Clinical Trials & Results
With every trial, we aim to solve challenges and unlock possibilities.
Our trials adhere to the highest standards of safety and equity, and our commitment to advancing healthcare is reflected in our rigorous study protocols and the relentless pursuit of new, effective treatments.
-
Ongoing Clinical Trials & Studies
Specialty Medicines
Study ID
Study Description
Intervention
Study Phase/Type
Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)
EN3835-309 PFI
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI)
Collagenase clostridium histolyticum EN3835
Phase 3/ Interventional
Recruiting
NCT06151197 -
Completed Clinical Trials & Studies
In the last 5 years
Specialty Medicines
Study ID
Study Description
Study Treatment
Clinical Study Results
EN3225-001
Open-Label Pilot Study Assessing the Efficacy and Safety of New Formulations of Percocet® in the Treatment of Low Back Pain
PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets
EN3225-002
A Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Study of the Safety and Efficacy of Low-dose Percocet® Compared to OxyContin® in Patients With Acute Pain Following Third Molar Extraction
PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets
EN3225-003
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Efficacy of Low-Dose Percocet® in Patients With Acute Pain Following Third Molar Extraction
PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets
EN3835-210
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Collagenase clostridium histolyticum EN3835
Completed
NCT04496167EN3835-222
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Collagenase clostridium histolyticum EN3835
Completed
NCT05152173EN3835-223
An Observational, Double-blind (Sponsor Open), Long-term Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to Placebo in the Treatment of Adhesive Capsulitis of the Shoulder (Frozen Shoulder)
No treatment to be administered
Completed
NCT04680156EN3835-306
A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis.
Collagenase clostridium histolyticum EN3835
Completed
NCT05254457EN3000-101
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products
AVEED®
TESTIM®
FORTESTA®Completed
NCT04456296EN3835-227 PFA
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess The Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)
Collagenase clostridium histolyticum EN3835
Completed
NCT06169319Sterile Injectables
Study ID
Study Description
Study Treatment
Clinical Study Results
PS4229-101
A Phase 1, Open-Label, Two-Arm, Parallel-Group, Pharmacokinetic Study on Plasma Clearance of Vasopressin in Healthy Volunteers
Vasostrict® (vasopressin injection, USP)
Completed
NCT04093050